A Single-centre, Randomized, Double-blind (Sponsor Unblinded), Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 24 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Dec 2015 Planned number of patients changed from 72 to 76, according to ClinicalTrials.gov record.
- 18 Dec 2015 Planned End Date changed from 1 Sep 2015 to 1 Feb 2016 , according to ClinicalTrials.gov record.